NEW YORK and PETACH TIKVAH, Israel, May 9, 2018 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, president and CEO, will present data from the company’s Phase 2 clinical study of NurOwn® in amyotrophic lateral sclerosis (ALS), at the World Advanced Therapy and Regenerative Medicine Congress in London, England. Mr. Lebovits will be hosting institutional investor and industry leader partnering meetings at the congress.
World Advanced Therapies & Regenerative Medicine Congress 2018
|Date:||Thursday, May 17|
|Location:||Business Design Centre, London|
|Title:||Brainstorm’s NurOwn® Treatment for Neurodegenerative Diseases|
|Presenter:||Chaim Lebovits, Chief Executive Officer, BrainStorm Cell Therapeutics|
About the World Advanced Therapies & Regenerative Medicine Congress
The 13th annual World Advanced Therapies & Regenerative Medicine Congress will bring together 1000+ attendees and explores the rapidly developing world of next generation therapeutics and advanced therapy medical products (ATMPs). From clinical development to pricing, reimbursement and market access this congress will bring the most exciting case studies and new data for immunotherapy, cell therapy, gene therapy, CARs and bioprocessing. Experts in every area will help companies tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic. This year’s conference will take place May 16 – 18 at the Business Design Center, London.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company’s website at www.brainstorm-cell.com.
Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at https://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.